Pramipexole (PRA) is a preferential D3R agonist that, in rats and humans, modifies prepulse inhibition (PPI) of the acoustic startle reflex, an operational measure of sensorimotor gating. The ability to use similar PPI measures across species, and the relative ease of genetic manipulations in mice, suggests that molecular studies of the D3R regulation of sensorimotor gating might be best pursued in mice. Here, we evaluate the effects of PRA on PPI and locomotion in C57BL/6J mice, the background strain for many gene knockout mouse models. Male C57BL/6J mice were tested for PPI and locomotor activity after injection of PRA. No significant effects of PRA on PPI were observed at any dose (0.1-10.0 mg/kg), but a significant reduction in startle magnitude was observed after 10 mg/kg PRA. In contrast, the D1/2 agonist, apomorphine (5 mg/kg) significantly reduced PPI in these mice. At doses of PRA that did not alter startle magnitude (0.3, 1, 3 mg/kg), significant decreases in the amount of locomotor and investigatory behavior were observed. Distinct from findings in rats and humans, it seems that either: (i) PRA does not activate D3Rs in C57BL/6J mice, or (ii) D3R agonists are not sufficient to alter PPI in this mouse strain.
Introduction
The study of dopamine (DA) D3 receptors (D3R) may shed new light on the pathogenesis and therapy of several neuropsychiatric disorders, but, owing to the homology between D3 and D2 receptors, there are only a small number of well-characterized specific D3 and D2 agonists and antagonists. Pramipexole (PRA) is a nonergot DA D2/ D3 receptor full agonist that has been reported to have a D3:D2 binding preference ranging from 7 : 1 to 160 : 1 in vitro (Svensson et al., 1994; Piercey et al., 1996; Millan et al., 2002) . In rats, PRA is a preferential D3 receptor agonist that reduces prepulse inhibition (PPI) of acoustic startle, an operational measure of sensorimotor gating ). In humans, PRA significantly increases PPI , an effect observed with other DA receptor agonists in some populations (Bitsios et al., 2005) . Though various in vitro and pharmacological techniques have been employed to assess the receptor specificity of PRA, in vivo molecular manipulations would provide definitive evidence of D3 versus D2 contributions to effects of PRA on sensorimotor gating. Such molecular mechanisms might also shed light on the molecular basis for the D3 regulation of PPI, which in humans seems to be linked to the D3 receptor Ser9Gly polymorphism (Roussos et al., 2008) .
In mice, DA D3 receptor knockout models have been informative about receptor subtype contributions for the actions of many dopaminergic drugs (Ralph et al., 1999; Carta et al., 2000; Schmauss, 2000; Le Foll et al., 2002; Glickstein and Schmauss, 2004; Siuciak and Fujiwara, 2004; Karasinska et al., 2005; McNamara et al., 2006; Risbrough et al., 2006; Zhou et al., 2007; Doherty et al., 2008; Leggio et al., 2008; Harrison and Nobrega, 2009) . PRA has been found to alter nocturnal locomotion, alter operant responding (Lehr, 2002) , induce hypothermia (Maj et al., 1997) , and decrease the duration of immobility in the forced swim test (Siuciak and Fujiwara, 2004; Kitagawa et al., 2009) . The ability to use similar PPI measures across species and the relative ease of genetic manipulations in mice makes them an attractive animal model to further study the role of D3 receptor activation in the regulation of sensorimotor gating. To date, there are no published reports of PRA effects on PPI in any strain of mice. Earlier studies of PRA effects on locomotor activity had mixed results with different strains of mice. The current report describes the effects of PRA on PPI and locomotor activity in C57BL/6J mice, a common background strain for knockout mice.
Methods

Subjects
Male C57BL/6J mice (n = 76) between 7 and 12 weeks of age were obtained from Jackson Labs (Bar Harbor, Maine, USA) and housed at a vivarium at the University of California San Diego, an Association for Assessment and Accreditation of Laboratory Animal Care-approved animal facility that meets federal and state requirements for care and treatment of laboratory animals. Mice were allowed to acclimate for approximately 1 week after arrival. All mice were housed n = 4 per cage, in a climate-controlled room with a reversed light cycle (lights on at 20:00 h, off at 08:00 h). Food (Harlan Teklad, Madison, Wisconsin, USA) and water were provided freely, except during behavioral testing. All testing occurred between 10:00 and 18:00 h; animal testing was conducted in accord with the 'Principles of Laboratory Animal Care' NIH guidelines and were approved by the University of California San Diego Institutional Animal Care and Use Committee.
Drugs
PRA was purchased from Toronto Research Chemicals (North York, Ontario, Canada), and apomorphine (APO) hydrochloride hemihydrates were purchased from SigmaAldrich (St Louis, Missouri, USA). Drug doses are based on milligram/kilogram salts. All drugs were injected subcutaneously in a volume of 5 ml/kg body weight. Based on published studies in other mouse strains, PRA (saline vehicle, 0.01, 0.03, or 1.0 mg/kg) was administered 10 min before PPI testing (Maj et al., 1997; Siuciak and Fujiwara, 2004) in Experiment 1. Owing to a lack of any evidence of bioactivity of these doses of PRA in Experiment 1, Experiment 2 assessed whether the correct pretreatment time had been used by measuring effects of PRA (saline vehicle, 0.1, 0.3, 1.0 mg/kg) on PPI in the 60 min immediately after drug administration. In Experiments 3 and 4, doses were increased for PRA (Experiment 3: saline vehicle, 0.3, 1.0, 3.0 mg/kg; Experiment 4: saline vehicle, 10 mg/kg) and administered 15 min before PPI testing. APO (0.01% ascorbate/saline vehicle, 5 mg/kg) was administered 5 min before PPI testing (Experiment 4). A range of stimulus types was used in Experiments 1-4, described below, to attempt to identify PRA-sensitive parameters. In Experiment 5, PRA (saline vehicle, 0.3, 1.0, 3.0 mg/kg) was administered immediately before locomotion testing.
Startle apparatus
Startle reactivity was measured using four startle chambers (SR-LAB, San Diego Instruments, San Diego, California, USA). Each chamber consisted of a clear nonrestrictive Plexiglas cylinder (inner diameter = 3.8 cm) resting on a platform inside a ventilated box. A highfrequency loudspeaker inside the chamber produced both a continuous background noise of 65 dB (A scale) and the various acoustic stimuli. Vibrations of the Plexiglas cylinder caused by the whole-body startle response of the animal were transduced into analog signals by a piezoelectric unit attached to the platform. These signals were then digitized and stored by a computer. Sixty-five readings were taken at 1-ms intervals, starting at stimulus onset, and the average amplitude was used to determine the acoustic startle response. The SR-LAB calibration unit was used routinely to ensure consistent stabilimeter sensitivity between test chambers and over time, and sound levels in dB sound pressure level (A scale) were measured as described earlier (Geyer and Dulawa, 2003) .
Startle testing procedure
All PPI test sessions consisted of startle trials (PULSE-ALONE), prepulse trials (PREPULSE + PULSE), and no stimulus trials (NOSTIM). The PULSE-ALONE trial consisted of a 40 ms, 120 dB (A) pulse of broadband noise. The NOSTIM trial consisted of background noise only. Parameters of PREPULSE + PULSE trials and the duration of the sessions varied with each experiment.
The test session began and ended with four to six presentations of the PULSE-ALONE trial; in between, each acoustic or NOSTIM trial type was presented in a pseudorandom order. There was an average intertrial interval of 15 s (range: 12-30 s). A background noise level of 65 dB (A) was presented for a 5-min acclimation period and continued throughout the matching and test sessions. Seven days after shipment arrival, mice were exposed to a 11 min 'matching' startle session consisting of (10) PULSE-ALONE trails that were interspersed with (6) PREPULSE + PULSE trials consisting of PULSE-ALONE preceded 100 ms (onset-to-onset) by a 20-ms noise burst that was 81 dB (A) in intensity [i.e. 16 dB above the 65 dB (A) background]. One 'nonresponder' was excluded from further testing owing to a mean startle response to PULSE-ALONE trials of less than 10 units during the matching session. Mice were assigned to drug treatment groups balanced for baseline PPI and startle magnitude during this matching session, as well as previous drug history. Groups were reassigned for each experiment. Test sessions were at least 1 week apart.
Experiments 1 and 4: PREPULSE + PULSE trials consisted of PULSE-ALONE preceded 100 ms by a 20-ms noise burst that was 69, 73, or 81 dB (A) in intensity [i.e., 4, 8, or 16 dB above the 65 dB (A) background]. Session duration was approximately 18.5 min.
Experiment 2: the test session was divided into 6-10-min blocks after the 5 min acclimation period. The initial 5 min of each block included four trial types: PULSE-ALONE, PREPULSE + PULSE (i.e. PULSE-ALONE preceded 100 ms by a 20-ms noise burst 8 dB above background), PREPULSE-ALONE, and NOSTIM.
Experiments 3 and 4: PREPULSE + PULSE trials consisted of PULSE-ALONE preceded 10, 20, 30, 60, 120 ms (onset-to-onset) by a 20-ms noise burst at 73 dB (A) (8 dB above background). Session duration was approximately 15.5 min.
presence of 'nonresponders', defined by a mean startle response to PULSE-ALONE trials of less than 10 units; apart from one mouse excluded after the matching session, none met this criteria. Other ANOVAs were used to assess PULSE-ALONE startle magnitude or activity in NOSTIM trials. Post-hoc comparisons were conducted using Fisher's protected least significance difference, with the threshold for a set at 0.05. Data were collapsed across prepulse intensities and PPI blocks.
Locomotion apparatus
Investigatory behavior and locomotor activity were measured in 10 mouse Behavior Pattern Monitor (BPM) chambers (San Diego Instruments). The design of the mouse BPM system was based on the rat BPM (for a detailed description, see Ref. Geyer et al., 1986) . The mouse BPM chamber was a clear Plexiglas box containing a 30 Â 60 cm holeboard floor. Each chamber was enclosed in a ventilated outer box to protect it from light and ambient noise from outside the chambers. The chamber contained 11 1.4-cm holes (three in the floor and eight in the walls), each provided with an infrared photobeam to detect investigatory nose pokes (hole pokes). The location of the mouse was obtained from a grid of 12 Â 24 photobeams 1 cm above the floor. Rearing was detected by an array of 16 photobeams placed 2.5 cm above the floor and aligned with the long axis of the chamber. The status of photobeams was sampled every 55 ms. A change in the status of photobeams triggered the storage of the information in a binary data file, together with the duration of the photobeam status. Subsequently, the raw data files were transformed into (x, y, t, event) American Standard Code for Information Interchange data files comprised of the (x, y) location of the animal in the mouse BPM chamber with a resolution of 1.25 cm, the duration of each event (t), and whether a hole poke or rearing event occurred.
Locomotor/exploratory activity testing procedure
Experiment 5: mice were tested in the dark and during the dark phase of their light cycle. The animals were brought into the testing room under black cloth 1 h before testing. During testing, a white noise generator produced background noise at 65 dB. Pretreatment and test injections were made under red lights in the testing room. Data were collected for 90 min. The chambers were cleaned thoroughly between testing sessions.
Analysis of locomotor activity
Horizontal locomotor activity was quantified as distance traveled. The number of hole pokes and rearings were calculated as measures of exploratory behavior. Data were examined using mixed-model ANOVAs with treatment as a between-subject factor and time as a repeated measure. Specific post-hoc comparisons between the selected Prepulse intensity groups in each time block were done using Tukey's studentized range method. Statistical significance was assessed using an a level of 0.05.
Results
Prepulse inhibition
ANOVA of % PPI failed to reveal significant main effects of PRA dose in Experiment 1 [F(3,35) = 1.87, NS] (Fig. 1 ). There were also no significant effects of PRA on startle magnitude [F(3,35) = 2.32, NS] (Fig. 1,  inset) or activity during NOSTIM trials [F(3,35) = 3.85, NS]. As expected, there was a significant effect of prepulse intensity [F(6,35) = 116.07, P < 0.001], but no significant dose Â intensity interaction (F < 1). There was a significant block effect on startle magnitude [F(3,35) = 8.82; P < 0.01], reflecting normal reflex habituation, but there was no significant dose Â block interaction (F < 1) (data not shown). The lack of effect of PRA on PPI was hypothesized to be as a result of one of three factors: (i) incorrect pretreatment time, missing the time period of maximal bioactivity, (ii) incorrect prepulse-to-pulse time interval, or (iii) inadequate dose of the drug. These three possibilities were addressed in Experiments 2-4. The total sample of mice was split between Experiments 2 and 3.
In Experiment 2, PPI was measured in six 10-min blocks, starting 5 min after administration of PRA. Again, there were no significant main effects of PRA (F < 1) (Fig. 2) , and there was no significant dose Â block interaction (F < 1). As in Experiment 1, there was no significant effect of PRA dose on startle magnitude [F(3.16) = 2.31, NS]; there was also no significant effect of block [F(5.16) = 1.54, NS], or dose Â block interaction (F < 1) (Fig. 2, inset) .
In Experiment 3, the interval between the onset of the (constant intensity) prepulse and the pulse was varied between 10, 20, 30, 60, and 120 ms. PRA doses were also increased to 0.3, 1.0, and 3.0 mg/kg. As expected, there was a significant effect of prepulse interval [F(4,15) = 11.67, P < 0.001] in the pattern that has been reported in rats (e.g. Swerdlow et al., 2009) . Again, ANOVA failed to reveal a significant main effect of PRA on PPI (F < 1), significant dose Â interval interaction [F(12,15) = 1.37, NS] (Fig. 3 ) or significant effect of PRA on startle magnitude [F(3,15) = 1.95, NS] (Fig. 3, inset) .
For the final PPI experiment (Experiment 4), the two groups from Experiments 2 and 3 were recombined. Mice were regrouped to balance for baseline PPI and drug history. As no evidence of bioactivity had yet been shown Effects of 0.1-1.0 mg/kg pramipexole (PRA) on prepulse inhibition (PPI) and startle magnitude (inset) across 60 min of testing in C57BL/6J mice (Experiment 2). To assess the time course for maximal bioactivity, PPI was tested in six 10-min time blocks after administration of 0.1, 0.3, and 1.0 mg/kg PRA. As in Experiment 1, there was no evidence of bioactivity of PRA at these doses. Data are mean ± SEM (n = 5 mice per dose group).
for any doses of PRA used in Experiments 1-3, the PRA dose was increased to 10 mg/kg. APO (5 mg/kg) was used as a reference drug to determine whether testing was adequately sensitive to detect a dopaminergic regulation of PPI. ANOVAs revealed a significant main effect of drug on % PPI (P < 0.001). Post-hoc tests revealed a significant reduction in % PPI after APO (P < 0.001), but not after 10 mg/kg PRA (NS) (Fig. 4) . However, there was also a significant main effect of drug on startle magnitude (P < 0.001), and post-hoc tests indicated that both PRA (P < 0.01) and APO (P < 0.05) significantly reduced startle magnitude (Fig. 4, inset) . In addition, it was observed grossly that mice receiving 10 mg/kg of PRA seemed lethargic and had reduced activity immediately after 5 min drug administration.
Locomotor and exploratory activity
In Experiment 5, a different set of mice were tested for locomotor activity at doses of PRA (0.3, 1, 3 mg/kg) that did not show any effects on either PPI or startle magnitude. ANOVAs revealed a significant main effect of drug dose (P < 0.001) and dose Â time interaction (P < 0.001) on locomotor activity and both measures of exploratory activity. All doses caused significant reductions in locomotor activity during the first 30 min after administration compared with the vehicle condition. At 0.3 mg/kg PRA, mice showed decreased locomotor activity during the first 30 min and hyperactivity during the last 40 min compared with the vehicle condition. Mice receiving 1.0 mg/kg PRA had decreased locomotor activity during the first 40 min that gradually increased to similar levels as vehicle-treated mice for the remainder of the 90-min testing period. At the highest dose of PRA tested, 3.0 mg/kg, mice showed a steady and decreased level of locomotor activity throughout the testing period. Habituation -reduced locomotor activity in vehicletreated mice as they acclimated to the BPM chamberwas not observed in mice treated with PRA (Fig. 5a ).
ANOVA of hole pokes revealed a significant main effect of drug dose, with a steady, dose-dependent decrease in the number of hole pokes throughout the 90-min test session (Fig. 5b) . There was no significant dose Â time interaction [F(24,32) = 1.164, NS]. The pattern of rearing looked similar to that of locomotion, with a significant dose Â time interaction (P < 0.001). The group treated with 0.3 mg/kg PRA showed fewer rears during the first 40 min, which increased by the end of the test session. Mice treated with 1 or 3 mg/kg PRA reared less than Effects of 0.3-3.0 mg/kg pramipexole (PRA) on prepulse inhibition (PPI) and startle magnitude (inset) across varying prepulse time intervals in C57BL/6J mice (Experiment 3). Owing to the absence of evidence of bioactivity in Experiments 1 and 2, PRA doses were shifted higher to 0.3, 1.0, and 3.0 mg/kg for Experiment 3. Prepulses were 8 dB (A) above background, and preceded the pulse by 10, 20, 30, 60, or 120 ms (onset-to-onset). Even at the highest dose, there was no significant effect on startle magnitude. Data are mean ± SEM (n = 4-5 mice per dose group).
Pramipexole effects on mouse PPI, locomotion Chang et al. 139 saline treated mice for the entire session, though this difference failed to reach significance for the last time block of the middle dose, owing to a slight increase in rears by this treatment group as well as a gradual decrease in rears by vehicle-treated mice (Fig. 5c) .
Discussion
The present studies expand upon previous reports of DA agonist effects on PPI and locomotion in mice by testing the preferential D3 agonist PRA for behavioral effects in C57BL/6J mice. The ability of APO to reduce PPI confirms several previous findings in this mouse strain (Ralph-Williams et al., 2002 Russig et al., 2004 Van den Buuse et al., 2005; Martin et al., 2008; Semenova et al., 2008; Caldwell et al., 2009 ) and other strains (Curzon and Decker, 1998; Ukai and Okuda, 2003; Malone et al., 2004; Park et al., 2005; Brea et al., 2006; Depoortere et al., 2007; Yano et al., 2009) . Although no effect of PRA on PPI was shown in this report, bioactivity was shown by a reduction in startle magnitude at the highest dose tested (10 mg/kg) and by changes in locomotor and exploratory behavior across lower doses. Startle magnitude reduction after administration of PRA at doses inducing PPI deficits is often observed in rats . A reduction in startle magnitude (indicating bioactivity) in the absence of any PPI effects in these C57BL/6J mice suggests that the pharmacological actions of PRA do not regulate PPI in this strain/species. Indeed, the mixed D2/D3 agonists, quinpirole and quinelorane, fail to disrupt PPI in several strains of mice, including C57BL/6J (Ralph-Williams et al., 2003; Ralph and Caine, 2005) . It should be noted, though, that quinelorane can disrupt PPI in some mouse strains (Ralph and Caine, 2007) , and quinpirole has been shown to increase PPI in mice when infused directly into the nucleus accumbens. In contrast, rats reliably exhibit reduced PPI after systemic PRA, quinpirole, or quinelorane administration, at least at the most commonly used prepulse intervals (Culm et al., 2004; Caine, 2005, Qu et al., 2008; Weber et al., 2008) . It has been reported through knockout studies in C57BL/6J mice that the DA D2 receptor subtype is necessary for amphetamine-induced PPI disruptions while the DA D1, D3, and D4 receptor subtypes are not (Ralph et al., 1999) . Effects of 10 mg/kg pramipexole (PRA) and 5 mg/kg apomorphine (APO) on prepulse inhibition (PPI) and startle magnitude (inset) across varying prepulse intensities in C57BL/6J mice (Experiment 4). PRA was administered at a maximum dose of 10 mg/kg for comparison against 5 mg/kg of APO with the same test parameters used in Experiment 1. About 10 mg/kg PRA showed evidence of bioactivity through startle reduction with no change in PPI, and APO served as a positive control of dopamine agonist-induced PPI disruption. Data are mean ± SEM. *P < 0.0001, **P < 0.009, ***P < 0.04 (n = 9 mice per dose group).
perhaps owing to unopposed effects of D1R activation. However, pharmacological manipulation of D3R activity does not always produce effects that are consistent with specific genetic manipulations of receptor subtypes (Corbin et al., 1998; Le Foll et al., 2002; Xi et al., 2005) . These results suggest that, while PRA may primarily be stimulating D3Rs in mice, this pharmacological activation does not alter PPI, and furthermore, D3 receptors may not play a prominent role in PPI regulation in this mouse strain.
Locomotion and exploratory behavior findings in the present studies are in keeping with previously published reports on PRA effects in other strains of mice (Maj et al., 1997; Lehr, 2002; Siuciak and Fujiwara, 2004) . 7-OH-DPAT and PD 128907, two other D3-preferential DA agonists, also reduce locomotor activity in wildtype C57BL/6J mice; this effect is not present in D3 receptor knockout mice (Pritchard et al., 2003) . In addition, D3 receptor antagonists enhance locomotor hyperactivity due to cocaine (Piercey et al., 1992) and amphetamine (Pritchard et al., 2007) , and mice deficient in D3 receptors exhibit an augmented cocaine-stimulated locomotion. Thus, compared with their role in regulating PPI in mice, D3 receptors seem to play a more prominent role in the regulation of locomotor activity.
The main goal of this study was to establish an assay in mice that could be used with molecular manipulations to assess the D3 specificity of PRA in its impact on PPI. Our findings, however, suggest that such an assay may not be informative, based on the surprising insensitivity of PPI to apparent D3 stimulation in mice. Although 'negative results' must always be interpreted with caution, this study used a number of different approaches to show that the lack of PRA effects on PPI did not reflect insensitivity of the PPI paradigm, lack of PRA bioactivity, or a restricted range of stimulus parameters or time course. In so doing, it is conceivable that these results identify a fundamental difference in the dopaminergic regulation of PPI across rat versus mouse species, analogous to other species differences in PPI previously reported in rats versus mice (RalphWilliams et al., 2002 (RalphWilliams et al., , 2003 Ralph and Caine, 2005) . Although differential sex effects of PRA were not explored in this study or other reports, PRA has not demonstrated sexually dimorphic effects or sensitivity to estrous phase in Sprague-Dawley rats . Given the disparate effects of PRA on PPI between male rats and mice, however, this lack of sex effect in rats is not necessarily translatable to mice. If molecular manipulations are to be applied towards clarifying the basis for the PPI-disruptive effects of D3 stimulation, it would seem that such studies may need to be pursued in rats, or at least in a different mouse strain. 
